Compare Recursion Pharmaceuticals Inc (RXRX) vs ZIM Integrated Shipping Services Ltd (ZIM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs ZIM Integrated Shipping Services Ltd — how do they compare? Recursion Pharmaceuticals Inc trades at $3.29 (market cap $1.81B), while ZIM Integrated Shipping Services Ltd trades at $25.32 (market cap $2.96B). The key difference: ZIM Integrated Shipping Services Ltd is the larger of the two by market cap, and ZIM Integrated Shipping Services Ltd pays a 20.16% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | ZIM | |
|---|---|---|
Market Cap | $1.81B | $2.96B |
Sector | Health | Industrials |
52-Week High | $6.79 | $29.27 |
52-Week Low | $2.84 | $12.44 |
Enterprise Value | $1.33B | $6.81B |
Dividend Yield | — | 20.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.295, up 0.15% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings miss with revenue declining year-over-year, while maintaining a strong cash position from financing activities. Recent news highlights participation in investor conferences and partnership advancements with Genentech.
Outlook remains speculative with high revenue growth potential from AI-driven drug discovery partnerships, but significant risks persist due to deep losses and negative margins. Analyst sentiment is mixed with a 40% buy rating, emphasizing the stock's high-risk, high-reward profile dependent on future clinical and commercial milestones.
ZIM trades at $25.29, up 0.32% on the day, amid a bearish technical outlook and mixed earnings performance. The stock shows weak profitability with a net margin of 1.56% and declining revenue projections for 2026. Recent news highlights uncertainty around a potential merger with Hapag-Lloyd and upcoming Q2 2026 earnings, with analyst sentiment evenly split between hold and sell recommendations.
The outlook for ZIM is cautious, with risks from merger uncertainty and operational pressures outweighing its low valuation multiples. Investment opportunity hinges on successful execution and merger approval, but current fundamentals and bearish technicals suggest limited near-term upside amid high volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About ZIM Integrated Shipping Services Ltd
ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →
